[18F]FAPI adds value to [18F]FDG PET/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study

Table 5 Analysis of the relationship between [¹⁸F]FAPI PET/CT and [¹⁸F]FDG PET/CT parameters with lymph node metastases

Variables	Benign (n = 197)	Metastases (n = 45)	P
LN risk categories			0.001
High	119(60.4)	39(86.7)
Low to intermediate	78(39.6)	6(13.3)
LN short-axis			< 0.001
< 1.0 cm	182(92.4)	16(35.6)
≥ 1.0 cm	15(7.6)	29(64.4)
LN calcification or high attenuation			0.001
Absent	143(72.6)	43(95.6)
Present	54(27.4)	2(4.4)
FDG SUV_max(median, IQR)	5.31(4.04, 7.87)	7.73(4.81, 16.74)	0.001
FAPI SUV_max(median, IQR)	1.96(1.42, 3.92)	9.85(6.05, 19.24)	< 0.001

Abbreviation: LN = lymph node, FAPI = fibroblast activation protein inhibitor, FDG = fluorodeoxyglucose, SUV_max= the maximum standard uptake value, IQR = interquartile range

ISSN: 1470-7330